维奈克拉联合去甲基化药物治疗较高危骨髓增生异常综合征的疗效与安全性真实世界分析
回顾性分析2021年3月至2022年12月中国医学科学院血液病医院连续收治的45例较高危MDS患者,采用维奈克拉联合去甲基化药物治疗,总缓解率62.2%、完全缓解率33.3%,中位随访189天中位总生存499天,应答者生存优于无应答者,需警惕严重血细胞减低等不良反应。
要点
- 45例较高危MDS患者中91%为IPSS-R高危或极高危,总体ORR 62.2%、CR率33.3%。
- 初治25例ORR 68%、CR率32%;非初治20例ORR 55%、CR率35%,达最佳疗效中位1个周期。
- 中位随访189天中位OS 499天,应答者499天 vs 无应答者228天(P<0.001)。
核心结论
- 维奈克拉联合去甲基化药物治疗较高危MDS患者存在临床获益。
- 治疗过程中需警惕严重血细胞减低等不良反应。
研究设计与样本
- 回顾性收集并分析2021年3月至2022年12月中国医学科学院血液病医院连续收治的45例应用维奈克拉联合去甲基化药物方案治疗的较高危MDS(IPSS-R评分>3.5分)患者的临床资料。
- 采用Kaplan-Meier法和Cox回归模型进行生存预后的单因素及多因素分析。
主要发现
- 45例患者中91%为IPSS-R评分高危或极高危患者,按国际工作组2023版修订评价标准ORR为62.2%(28/45)、CR率为33.3%(15/45)。
- 25例初治患者ORR为68%(17/25)、CR率为32%(8/25);20例非初治患者ORR为55%(11/20)、CR率为35%(7/20);达最佳疗效中位周期数为1(1~4)个。
- 中位随访189天,中位OS期为499(95%CI 287~711)天,患者死亡多因本病进展。
- 维奈克拉应答者中位OS期明显长于无应答者(499天 vs 228天,P<0.001)。
- 多因素分析显示IPSS-R评分、对治疗反应为影响OS的独立预后因素;存在SETBP1基因突变可能延长患者住院时间(51.5天 vs 27天,P=0.017)。
关键数值与推荐
- 较高危MDS定义为修订后国际预后评分系统(IPSS-R)评分>3.5分。
- 疗效评价采用国际工作组(IWG)2023版修订评价标准。
- 总体ORR 62.2%(28/45),CR率33.3%(15/45);初治患者ORR 68%(17/25)、CR率32%(8/25),非初治患者ORR 55%(11/20)、CR率35%(7/20)。
临床怎么用
- 原文结论认为维奈克拉联合去甲基化药物对较高危MDS患者存在临床获益。
- 原文结论提出需警惕治疗过程中发生严重血细胞减低等不良反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy and safety of combining venetoclax (VEN) with hypomethylated drugs (HMA) in the treatment of higher-risk (IPSS-R score >3.5) myelodysplastic syndromes (MDS) . Methods: From March 2021 to December 2022, forty-five MDS patients with intermediate and high risk were treated with VEN in combination with HMAs. Clinical data were collected and analyzed retrospectively, including gender, age, MDS subtype, IPSS-R score, treatment regimen, and efficacy, etc. Kaplan-Meier method and Cox regression model were used to analyze univariate and multivariate of survival prognosis. Results: ①Forty-five patients with MDS, including ninety-one percent were classified as high or very high risk. According to the 2023 consensus proposal for revised International Working Group response criteria for higher-risk MDS, the overall response rate (ORR) was 62.2% (28/45), with the complete response rate (CR) was 33.3% (15/45). For twenty-five naïve MDS, the ORR was 68% (17/25) and the CR rate was 32% (8/25). In nonfirst-line patients, the ORR and CR were 55% (11/20) and 35% (7/20) respectively. The median cycle to best response was 1 (1-4). ②With a median followup of 189 days, the median overall survival (OS) time was 499 (95% confidence interval, 287-711) days, and most patients died from disease progression. Responders had a significantly better median OS time than nonresponders (499 days vs 228 days, P<0.001). Multifactor analysis revealed that IPSS-R score and response to treatment were independent prognostic factors for OS; the presence of SETBP1 gene mutations was associated with a longer hospital stay (51.5 days vs 27 days, P=0.017) . Conclusions: There is clinical benefit of venetoclax in combination with hypomethylated agents in patients with higher-risk MDS, but adverse events such as severe hypocytopenia during treatment should be avoided. 目的: 探讨维奈克拉(VEN)联合去甲基化药物(HMA)治疗较高危[修订后国际预后评分系统(IPSS-R)评分>3.5分]的骨髓增生异常综合征(MDS)的疗效及安全性。 方法: 纳入2021年3月至2022年12月于中国医学科学院血液病医院连续收治的共计45例应用VEN联合HMA方案治疗的较高危MDS患者,回顾性收集并分析临床资料,主要包括性别、年龄、MDS亚型、IPSS-R评分、治疗方案及疗效等,采用Kaplan-Meier法和Cox回归模型进行生存预后的单因素及多因素分析。 结果: ①共计45例MDS患者,其中91%患者为IPSS-R评分高危或极高危患者。按照国际工作组(IWG)2023版修订评价标准:总缓解率(ORR)为62.2%(28/45),完全缓解(CR)率为33.3%(15/45)。25例初治患者ORR为68%(17/25),CR率为32%(8/25)。20例非初治MDS患者ORR为55%(11/20),CR率为35%(7/20)。患者达最佳疗效中位周期数为1(1~4)个。②中位随访时间189 d,中位总生存(OS)期为499(95% CI 287~711)d,患者死亡多因本病进展。VEN应答者中位OS期明显长于无应答者(499 d对228 d,P<0.001)。③多因素分析显示IPSS-R评分、对治疗反应为影响OS的独立预后因素;存在SETBP1基因突变可能延长患者住院时间(51.5 d对27 d,P=0.017)。 结论: VEN联合HMA治疗较高危MDS患者存在临床获益,但需警惕治疗过程中发生严重血细胞减低等不良反应。.
引用
- Gao QY, Li B, Qu SQ, et al. [Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 38604792. doi:10.3760/cma.j.cn121090-20230926-00136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。